Novo Nordisk's Victoza granted label extension in the UK

A license extension has been granted in the UK for Victoza (liraglutide), an already blockbuster diabetes drug from Danish insulin giant Novo Nordisk (NOV: N).

The once-daily injection has been approved for adults with type 2 diabetes and moderate renal impairment, and means Victoza is now available to the almost one million people in the UK with both conditions. It increases prescribing clinicians’ options to help patients with these conditions control glucose.

The license extension was based on efficacy and safety data from the LIRA-RENAL Phase IIIb clinical trial among adults with moderate renal impairment. Victoza 1.8mg showed superior blood glucose reduction with no worsening of renal function versus placebo in adults receiving anti-diabetes tablets and/or insulin to control their type 2 diabetes, over 26 weeks.